Rusi Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 28-12-2024
- Paid Up Capital ₹ 5.00 M
as on 28-12-2024
- Company Age 32 Year, 3 Months
- Last Filing with ROC 31 Mar 2020
- Satisfied Charges ₹ 6.01 Cr
as on 28-12-2024
- Revenue 130.93%
(FY 2016)
- Profit 1.24%
(FY 2016)
- Ebitda 15.61%
(FY 2016)
- Net Worth -28.92%
(FY 2016)
- Total Assets -23.97%
(FY 2016)
About Rusi Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company has closed loans amounting to ₹6.01 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Monika and Sudhir Kumar serve as directors at the Company.
- CIN/LLPIN
U24230MH1992PTC069066
- Company No.
069066
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Oct 1992
- Date of AGM
03 Oct 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Rusi Pharma Pvt Ltd offer?
Rusi Pharma Pvt Ltd offers a wide range of products and services, including Bird Food, Poultry & Animal Food, Animal Feed Supplement, Nutraceuticals & Dietary Supplements, Mineral Supplement, Ayurvedic,Herbal Products & Medicine, Ayurvedic Medicine, Liquid Calcium, Plastic Bottles, Spray Bottles, Feed Additives.
Who are the key members and board of directors at Rusi Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Monika  | Additional Director | 28-Jun-2021 | Current |
| Sudhir Kumar | Additional Director | 25-Jan-2019 | Current |
Financial Performance of Rusi Pharma.
Rusi Pharma Pvt Ltd, for the financial year ended 2016, experienced significant growth in revenue, with a 130.93% increase. The company also saw a slight improvement in profitability, with a 1.24% increase in profit. The company's net worth observed a substantial decline by a decrease of 28.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rusi Pharma?
In 2017, Rusi Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Baroda Creation Date: 30 Jul 2004 | ₹5.70 Cr | Satisfied |
Central Bank Of India Creation Date: 05 Feb 2000 | ₹2.00 M | Satisfied |
The Saraswat Co-Op Bank Ltd Creation Date: 27 May 1997 | ₹0.30 M | Satisfied |
How Many Employees Work at Rusi Pharma?
Rusi Pharma has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rusi Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rusi Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
